Showing stories 1 - 7 of about 7
Synergy On Sale: Why This Opportunity Shouldn't Be Missed
As many on Wall Street know, Board Chairman Gabriel Cerrone has a track record of ushering in high take-out premiums for development-stage biotech companies (he championed the $2.5 billion sale of Inhibitex to Bristol-Myers Squibb (BMY) in early 2012 ...